These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30145588)

  • 1. Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: A 25-Year Follow-Up Study.
    Johansson L; Kern S; Zetterberg H; Blennow K; Börjesson-Hansson A; Rosengren L; Guo X; Skoog I
    Dement Geriatr Cogn Disord; 2018; 46(1-2):90-99. PubMed ID: 30145588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid β42 and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death.
    Ribbe M; Kern S; Börjesson Hansson A; Östling S; Zetterberg H; Blennow K; Skoog I
    Dement Geriatr Cogn Disord; 2019; 47(1-2):114-124. PubMed ID: 30970371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
    Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
    Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.
    Hoscheidt SM; Starks EJ; Oh JM; Zetterberg H; Blennow K; Krause RA; Gleason CE; Puglielli L; Atwood CS; Carlsson CM; Asthana S; Johnson SC; Bendlin BB
    J Alzheimers Dis; 2016 Apr; 52(4):1373-83. PubMed ID: 27079723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid biomarkers of Alzheimer's disease in Chinese patients: a pilot study.
    Shea YF; Chu LW; Zhou L; Li WM; Lin OY; Chan MN; Xu A; Wong R; Ho TY; Liu KW; Ha J; Daniel TW; Song YQ; Lam KS
    Am J Alzheimers Dis Other Demen; 2013 Dec; 28(8):769-75. PubMed ID: 24085246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
    Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
    Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.
    Baldeiras I; Santana I; Leitão MJ; Ribeiro MH; Pascoal R; Duro D; Lemos R; Santiago B; Almeida MR; Oliveira CR
    J Neurol Sci; 2015 Nov; 358(1-2):308-16. PubMed ID: 26388316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease.
    Biscetti L; Salvadori N; Farotti L; Cataldi S; Eusebi P; Paciotti S; Parnetti L
    Clin Chim Acta; 2019 Jul; 494():71-73. PubMed ID: 30844364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease.
    Tapiola T; Pirttilä T; Mikkonen M; Mehta PD; Alafuzoff I; Koivisto K; Soininen H
    Neurosci Lett; 2000 Feb; 280(2):119-22. PubMed ID: 10686392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
    Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y
    Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.